BioSpace News Archive

Vor secured $110 million in a Series B financing round that will be used to advance the company’s lead stem cell-based oncology asset into clinical trials.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.

Cellectis, based in Paris and New York, announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its MELANI-01 trial.

Novavax said the funding will allow the company to participate in Operation Warp Speed, the government’s program that has a goal of supporting the development of hundreds of millions of vaccine doses by 2021.

IM Therapeutics is developing a personalized, orally available small molecule therapeutic for diabetes. This is a milestone for autoimmune diseases and may be the first time diabetes patients can be preselected for a therapeutic based on whether they carry a specific gene.

This deal with BARDA and the DoD supports continuing the manufacturing in order for it to be immediately available in the U.S. if the clinical trials are successful.

Putting your employees and company culture first keeps the focus on inclusion and innovation, giving the company an incredible competitive advantage.

GlaxoSmithKline is providing its pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.

Unum Therapeutics announced on Monday that it has successfully completed its acquisition of Kiq LLC, a privately held biotechnology company with a focus on the discovery and development of precision kinase inhibitors.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that Dr. Akil Jackson, Medical Director at BerGenBio, will be participating at the Sachs Associates Digital Novel Coronavirus Investment Forum on 8-9 July 2020.